Definitive Contract 75N93022C00034

This is a $149,868.00 Firm Fixed Price SBIR Phase I contract awarded by the U.S. Army Medical Command to Hawaii Biotech, Inc., a small business biotechnology company. The contract supports the research and development of prophylactic vaccines for infectious diseases, specifically targeting Anthrax intoxication, botulism, and West Nile Virus. Hawaii Biotech has previously received federal grants from the National Institute of Allergy and Infectious Diseases (NIAID) to fund its vaccine research...

This federal contract award, valued at $43,027,525.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to Hawaii Biotech, Inc. (HBI), a biotechnology company focused on research and development of vaccines and therapeutics for infectious diseases. The contract is for the "DEVELOPMENT OF A SMALL MOLECULE DRUG ANTI-TOXIN THERAPEUTIC TO TREAT ANTHRAX IN HUMANS." It is a definitive, cost-plus-fixed-fee contract with a completion date of December 30, 2025....

This is a $2,154,144.00 cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Sri International, a non-profit R&D institute. The contract is for a GLP toxicology study on adjuvanted HIV-1 immunogen vaccine candidates, as part of NIAID's "Preclinical And Translational Vaccine Development For HIV And Other Candidate Agents" major program. This work is being performed...

This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases, valued at $299,999, was awarded to Neovaxsyn Inc. to develop a protective HIV vaccine utilizing gold nanoparticles to elicit broadly neutralizing antibodies against the fusion peptide of HIV-1 GP41. The contract was awarded under the Small Business Innovation Research Program Phase I solicitation, which sought proposals for research...

This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...

This is a $599,999 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Parabon NanoLabs, Inc., a small business. The objective of the contract is to develop a DNA-based HIV vaccine that will stimulate production of broadly neutralizing antibodies against the HIV-1 envelope protein trimer antigen. This is a Phase I Small Business Innovation Research (SBIR) contract under the...

Hafion Inc., a self-certified small disadvantaged and woman-owned small business, was awarded a $310,592 Firm Fixed Price Definitive Contract from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (HHS NIH NIAID) under the HHS SBIR Program. The contract, which was set aside for small businesses, is for research and development services related to the development of protein:non-protein macromolecular adjuvants. The...

This is a $300,000 firm fixed price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Neovaxsyn Inc., a minority-owned small disadvantaged business. The contract is for research and development to utilize nanoparticles to deliver MPER-based immunogens and elicit broadly neutralizing antibodies against the HIV-1 virus in order to develop a protective vaccine. This contract was awarded under the Small...

This federal contract award, valued at $16,731,358.00, was made by the National Institute of Allergy and Infectious Diseases (NIAID) to the Access To Advanced Health Institute (AAHI), a non-profit biotech research institute. The contract is for the continued development of vaccine candidates for biodefense, antimicrobial resistance, emerging infectious diseases, and respiratory pathogens. No set-aside designation was used. AAHI has subcontracted with several institutions, including Emory...

This is a $403,478.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Southern Research Institute, a non-profit research organization. The contract is for conducting hit-to-lead progression studies on investigational agents for the treatment of HIV. This work will be performed under NIAID's Preclinical Services for HIV Therapeutics indefinite...